NeuroOne: Thinner Is Better When It Comes To Brain Electrodes
NeuroOne manufactures the thinnest FDA-approved stereoelectroencephalography electrode for 30-day use, and a recent Emory University study could further expand their applications.
You may also be interested in...
NeuroOne’s CEO Talks About 510(k) Clearance Of Evo sEEG Electrodes
Medtech Insight spoke to Dave Rosa, CEO of NeuroOne, about working with the FDA to get a 510(k) clearance.
Minute Insight: NeuroOne Amends Deal With Zimmer Biomet To Shore Up Balance Sheet
Zimmer Biomet agreed to amend its exclusive development and distribution agreement with NeuroOne to pay $3.5m for 350,000 of stock. The deal will help NeuroOne continue to develop its Evo stereoelectroencephalography brain-mapping electrodes without further diluting the company’s stock.
The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted
Carl Icahn was successful in ousting Illumina’s chair, however its CEO, Francis deSouza remains. Both analysts and investors believe this could further encourage Illumina to divest Grail.